The lack of a direct, quantitative biomarker for MPS1 inhibition in order to identify a PD vs efficacy relationship prompted us to set up and optimise an inducible MPS1 model in DLD1 colon cancer cells, in order to directly measure MPS1 inhibition via MPS1 autophosphorylation. The gene discussed is TTK; the disease is colonic neoplasm.